The importance of aggressive lipid management in patients at risk: evidence from recent clinical trials

Clinical Cardiology
Keith C Ferdinand

Abstract

Clinical trials that evaluate more aggressive cholesterol reduction in a broader range of patients at high risk for coronary heart disease (CHD) are needed to fill gaps in our understanding of the impact of lipid-lowering therapy on risks for clinical events and mortality. This paper briefly reviews results from recent landmark studies that have evaluated the benefits of aggressive lipid-lowering therapy in patients with, or at risk for, CHD. The Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study demonstrated that aggressive treatment with atorvastatin was significantly more effective than less aggressive therapy with pravastatin in slowing the progression of atherosclerosis in patients with symptomatic CHD. Results from two large-scale clinical end-point trials, the Heart Protection Study (HPS) and the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), have shown that aggressive lipid-lowering treatment in patients with relatively low baseline levels of low-density lipoprotein cholesterol (LDL-C) significantly reduces CHD risk. Taken together, the results of these landmark trials not only support aggressive lipid lowering in patients at risk for CHD, but also suggest that greater L...Continue Reading

References

Aug 1, 1993·Journal of the American College of Cardiology·E D Frohlich
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 25, 2003·International Journal of Clinical Pharmacology and Therapeutics·M VrecerA Mrhar
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators

❮ Previous
Next ❯

Citations

Feb 10, 2006·Disease Management : DM·W Dallas HallUNKNOWN African-American Lipid and Cardiovascular Council
Apr 7, 2006·Nitric Oxide : Biology and Chemistry·Michael AugustNikolaos Tsilimingas
Jan 18, 2006·The Journal of Nutritional Biochemistry·Christopher P F MarinangeliPeter J H Jones
Apr 17, 2015·BMC Family Practice·Jorma SavolainenPekka Mäntyselkä
Dec 5, 2006·Biological & Pharmaceutical Bulletin·Kenji MatsumotoShin-ichiro Yokoyama
May 9, 2006·Suicide & Life-threatening Behavior·Jennifer L RoweYeates Conwell
Mar 14, 2018·Proceedings of the National Academy of Sciences of the United States of America·Kay Dickersin, Evan Mayo-Wilson
May 21, 2005·The British Journal of Psychiatry : the Journal of Mental Science·S K Chaturvedi
Jul 7, 2018·BioMed Research International·Bugra Ozkanİsmail Türkay Özcan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.